Auro Laboratories Limited , a pharmaceutical company based in Maharashtra, has announced a significant milestone in its operations. The company has successfully completed a World Health Organization (WHO) inspection at its Active Pharmaceutical Ingredients (API) manufacturing facility located in MIDC Tarapur, Maharashtra.

WHO-GMP Certification Details

The company has received a World Health Organization - Good Manufacturing Practices (WHO-GMP) Certificate from the Food & Drug Administration, Maharashtra. This certification is valid until September 30, 2028, covering the company's bulk drugs manufacturing operations at the Tarapur location.

Implications for Auro Laboratories

The WHO-GMP certification is a testament to Auro Laboratories' commitment to maintaining high standards in its manufacturing processes. This certification may potentially open up new opportunities for the company in the global pharmaceutical market, as it is often a prerequisite for entering certain international markets.

Company Background

Auro Laboratories Limited operates in the pharmaceutical sector, specializing in the manufacture of Active Pharmaceutical Ingredients. The company's manufacturing unit is located in MIDC Tarapur, Maharashtra, while its registered office is in Mumbai.

Market Impact

While the immediate market impact of this certification is not provided in the available data, such recognitions typically enhance a company's credibility and may positively influence its market position in the pharmaceutical industry.

Investors and stakeholders in Auro Laboratories Limited may want to monitor how this certification might translate into business growth and market opportunities for the company in the coming months and years.

Auro Laboratories Limited , a pharmaceutical company based in Tarapur, Maharashtra, has reported a net loss of Rs 71.58 lakhs for the quarter ended September 30, 2025. This marks a significant increase in losses compared to the previous quarter's loss of Rs 10.55 lakhs.

Financial Performance

The company's financial results, which were reviewed by the Audit Committee and approved by the Board of Directors on November 12, 2025, reveal a challenging quarter for Auro Laboratories. Here's a breakdown of the key financial metrics:

Despite a significant increase in revenue from operations, rising from Rs 217.42 lakhs in the previous quarter to Rs 883.67 lakhs in the current quarter, the company's expenses also saw a substantial rise. This led to the reported loss for the quarter.

Balance Sheet Highlights

As of September 30, 2025, Auro Laboratories reported:

• Total Assets: Rs 11,077.34 lakhs
• Total Equity: Rs 4,357.84 lakhs
• Non-Current Liabilities: Rs 3,841.97 lakhs
• Current Liabilities: Rs 2,877.53 lakhs

Operational Update

In a separate announcement, Auro Laboratories informed that it has successfully completed a World Health Organization (WHO) inspection at its Active Pharmaceutical Ingredients (API) manufacturing facility located in MIDC Tarapur, Maharashtra. The company has received a World Health Organization - Good Manufacturing Practices (WHO - GMP) Certificate from the Food & Drug Administration, Maharashtra, valid until September 30, 2028.

Investor Considerations

While the company has faced a challenging quarter, the recent WHO-GMP certification could be a positive development for future business prospects. However, it's important to monitor how the company manages its expenses and improves profitability in the coming quarters.

The full financial results are available on the BSE website ( www.bseindia.com ) and the company's website ( www.aurolabs.com ) for further detailed analysis.